


17-11-2021

13:00 - 14:30 Industry satellite symposium 1 Channel 1

13:00 - 14:30 Industry satellite symposium 2 Channel 2

15:00 - 15:05 Preceptorship on Gastric Cancer: Welcome and introduction Channel 1

Moderation: F. Lordick¹, M.C.H. Ng², ¹Medicine Department, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE, ²Medical Oncology Department, NCCS - National Cancer Centre Singapore, Singapore, SG

15:00 - 15:05 **Welcome and introduction**

15:00 - 15:10 Preceptorship on Urothelial Cancer: Welcome and introduction Channel 2

Moderation: L. Albiges¹, R. Kanavarat², ¹Medical Oncology, Institut Gustave Roussy, Villejuif, FR, ²Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG

15:00 - 15:05 **Welcome and introduction**

15:05 - 17:25	Preceptorship on Gastric Cancer: Epidemiology, pathology and multidisciplinary management of localised gastric cancer	Channel 1
	Moderation: M.C.H. Ng, Medical Oncology Department, NCCS - National Cancer Centre Singapore, Singapore, SG	
15:05 - 15:25	Epidemiology, pathogenesis and molecular subtypes <u>B. Ma</u> , The Chinese University of Hong Kong, Sha Tin, HK	
15:25 - 15:45	How pathology can guide treatment: HER2, MSI, PDL1 and EBV <u>T. Lim</u> , SGH - Singapore General Hospital, Singapore, SG	
15:45 - 16:05	Advances in surgery: Endoscopic, minimally invasive, optimal nodal dissection and organ-sparing (spleen, omentum) <u>J. So</u> , NCIS - National University Cancer Institute Singapore, Singapore, SG	
16:05 - 16:15	Discussion	
16:15 - 16:40	Neo- and adjuvant approaches to gastric cancer <u>M.C.H. Ng</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
16:40 - 17:05	Neo-adjuvant chemo or chemoradiation for type1/2 GEJ cancer and the use of immunotherapy and targeted therapy <u>F. Lordick</u> , Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE	
17:05 - 17:15	Discussion	
15:10 - 15:45	Preceptorship on Urothelial Cancer: Pathology and molecular pathology	Channel 2
	Moderation: R. Kanesvaran, Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG	
15:10 - 15:25	Urothelial carcinoma <u>P.H. Tan</u> , Singapore General Hospital, Singapore, SG	
15:25 - 15:35	Upper track versus bladder: Key differences <u>P.H. Tan</u> , Singapore General Hospital, Singapore, SG	
15:35 - 15:45	Discussion	

15:45 - 17:30	Preceptorship on Urothelial Cancer: Metastatic disease	Channel 2
	Moderation: L. Albiges, Medical Oncology, Institut Gustave Roussy, Villejuif, FR	
15:45 - 16:00	First-line	
	<u>J. Bellmunt</u> , Harvard Medical School, Boston, US	
16:00 - 16:15	Second-line and beyond	
	<u>Y. Loriot</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
16:15 - 16:25	New agents	
	<u>D. Poon</u> , The Chinese University of Hong Kong, Hong Kong, HK	
16:25 - 16:35	Discussion	
16:35 - 17:20	Participants clinical case discussion	
17:25 - 18:25	Preceptorship on Gastric Cancer: Participants clinical case discussion	Channel 1
	Moderation: F. Lordick ¹ , M.C.H. Ng ² , ¹ Medicine Department, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE, ² Medical Oncology Department, NCCS - National Cancer Centre Singapore, Singapore, SG	
17:25 - 18:25	Participants clinical case discussion	
17:30 - 18:05	Preceptorship on Urothelial Cancer: Biomarkers	Channel 2
	Moderation: R. Kanesvaran, Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG	
17:30 - 17:55	Biomarkers use to inform treatment decisions for MUC	
	<u>T. Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB	
17:55 - 18:05	Discussion	

19:30 - 21:00	Industry satellite symposium - Astellas: Navigating the therapeutic landscape of locally advanced/metastatic urothelial carcinoma (la/mUC)	Channel 1
	Moderation: R. Kanesvaran, Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG	
19:30 - 19:35	Welcome & context setting <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
19:35 - 19:55	Therapeutic landscape of la/mUC progressing after 1st line therapy <u>P. O'Donnell</u> , The University of Chicago, Chicago, US	
19:55 - 20:05	Asian perspectives on la/mUC management in 2021 <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
20:05 - 20:25	la/mUC case discussion: Platinum-eligible / Platinum-ineligible <u>S. Sridhar</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
20:25 - 20:55	Live panel discussion & Q&A from audience <u>R. Kanesvaran</u> ¹ , <u>P. O'Donnell</u> ² , <u>S. Sridhar</u> ³ , ¹ NCCS - National Cancer Centre Singapore, Singapore, SG, ² The University of Chicago, Chicago, US, ³ UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
20:55 - 21:00	Concluding remarks & feedback <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
19:30 - 21:00	Industry satellite symposium 4	Channel 2
19:30 - 19:50	Lecture	

18-11-2021

13:00 - 14:30 Industry satellite symposium 5 Channel 1

13:00 - 14:30 Industry satellite symposium 6 Channel 2

15:00 - 15:30 Preceptorship on Gastric Cancer: Cancer genetics Channel 1

Moderation: M.C.H. Ng, Medical Oncology Department, NCCS - National Cancer Centre Singapore, Singapore, SG

15:00 - 15:20 **A practical approach to hereditary gastric cancers**

J. Ngeow, Lee Kong Chian School of Medicine, SG

15:20 - 15:30 **Discussion**

15:00 - 15:40 Preceptorship on Urothelial Cancer: Perioperative management Channel 2

Moderation: R. Kanesvaran, Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG

15:00 - 15:15 **What is new in NMIBC**

L.S. Lee, SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG

15:15 - 15:30 **Overview of neoadjuvant trials in MIBC**

D. Poon, The Chinese University of Hong Kong, Hong Kong, HK

15:30 - 15:40 **Discussion**

15:30 - 17:10	Preceptorship on Gastric Cancer: Metastatic gastric cancer	Channel 1
	Moderation: F. Lordick, Medicine Department, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE	
15:30 - 15:50	Optimising chemotherapy and molecularly targeted therapy <u>W.P. Yong</u> , NUHS - National University Health System, Singapore, SG	
15:50 - 16:10	Immunotherapy monotherapy or in combination and when best to give it <u>S.Y. Rha</u> , Yonsei University, Seoul, KR	
16:10 - 16:30	Discussion	
16:30 - 16:50	Approaches to treat oligometastatic disease <u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	
16:50 - 17:00	Discussion	
15:45 - 16:15	Preceptorship on Urothelial Cancer: Debate: CPI in adjuvant for MIBC	Channel 2
	Moderation: L. Albiges, Medical Oncology, Institut Gustave Roussy, Villejuif, FR	
15:45 - 16:00	Pros <u>S. Sridhar</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
16:00 - 16:15	Cons <u>T. Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB	
16:15 - 16:25	Discussion	

16:30 - 17:50	Preceptorship on Urothelial Cancer: Side effects management	Channel 2
	Moderation: R. Kanesvaran, Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG	
16:30 - 16:45	CPI based regimen toxicity	
	<u>L. Albiges</u> , Institut Gustave Roussy, Villejuif, FR	
16:45 - 16:55	ADC toxicity	
	<u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
16:55 - 17:05	Discussion	
17:05 - 17:50	Participants clinical case discussion	
17:10 - 18:10	Preceptorship on Gastric Cancer: Participants clinical case discussion	Channel 1
	Moderation: M.C.H. Ng, Medical Oncology Department, NCCS - National Cancer Centre Singapore, Singapore, SG	
17:10 - 18:10	Participants clinical case discussion	
17:50 - 18:00	Preceptorship on Urothelial Cancer: Conclusion and farewell	Channel 2
	Moderation: L. Albiges ¹ , R. Kanesvaran ² , ¹ Medical Oncology, Institut Gustave Roussy, Villejuif, FR, ² Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG	
17:50 - 18:00	Conclusion	
18:10 - 18:15	Preceptorship on Gastric Cancer: Conclusion and farewell	Channel 1
	Moderation: F. Lordick ¹ , M.C.H. Ng ² , ¹ Medicine Department, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE, ² Medical Oncology Department, NCCS - National Cancer Centre Singapore, Singapore, SG	
18:10 - 18:15	Conclusion	

19:30 - 21:00	Industry satellite symposium - AstraZeneca: Collaboration is key: the multidisciplinary management of HCC	Channel 1
	Moderation: D. Liu, Vancouver General Hospital & HSC, British Columbia University, Vancouver, CA	
19:30 - 19:35	Welcome and introductions D. Liu, Vancouver General Hospital & HSC, British Columbia University, Vancouver, CA	
19:35 - 19:50	The role of the multidisciplinary tumour board in early-stage HCC: resection and other treatment options P. Chow, NCCS - National Cancer Centre Singapore, Singapore, SG	
19:50 - 20:10	An evolving landscape: treatment for intermediate-stage HCC M. Kudo, Kindai University - Faculty of Medicine, Osaka, JP	
20:10 - 20:30	Systemic therapy for unresectable/advanced HCC: recent developments and emerging combination therapy approaches G. Abou-Alfa, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
20:30 - 20:45	Live case study discussion D. Liu ¹ , P. Chow ² , M. Kudo ³ , G. Abou-Alfa ⁴ , ¹ Vancouver General Hospital & HSC, British Columbia University, Vancouver, CA, ² NCCS - National Cancer Centre Singapore, Singapore, SG, ³ Kindai University - Faculty of Medicine, Osaka, JP, ⁴ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
20:45 - 21:00	Live Q+A D. Liu ¹ , P. Chow ² , M. Kudo ³ , G. Abou-Alfa ⁴ , ¹ Vancouver General Hospital & HSC, British Columbia University, Vancouver, CA, ² NCCS - National Cancer Centre Singapore, Singapore, SG, ³ Kindai University - Faculty of Medicine, Osaka, JP, ⁴ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
19:30 - 21:00	Industry satellite symposium 8	Channel 2

19-11-2021

12:00 - 13:30	Industry satellite symposium 9	Channel 1
12:00 - 13:30	Industry satellite symposium - Boehringer Ingelheim: Expert Perspectives in Navigating the Evolving Treatment Landscape in Advanced NSCLC	Channel 2

12:00 - 13:30 **Lecture**

14:00 - 15:15	Current standards and practice changing studies in upper gastrointestinal cancer	Channel 1
---------------	---	------------------

14:00 - 14:20 **Practice changing studies in localized/early disease**
F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE

14:20 - 14:40 **Practice changing studies in locally advanced/metastatic disease**
W.P. Yong, NUHS - National University Health System, Singapore, SG

14:40 - 14:55 **An Asian patient clinical case focusing on 'Before' and 'After' the implementation of the practice-changing studies in the local/national context**
R. Wong, Eastern Health - Box Hill Hospital - Main Entrance, Box Hill, AU

14:55 - 15:15 **Discussion**

14:00 - 15:15	Current standards and practice changing studies in thoracic cancers	Channel 2
---------------	--	------------------

14:00 - 14:20 **Practice changing studies in localized/early disease**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

14:20 - 14:40 **Practice changing studies in locally advanced/metastatic disease**
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

14:40 - 14:55 **An Asian patient clinical case focusing on 'Before' and 'After' the implementation of the practice-changing studies in the local/national context**
N. Prasongsook, Phramongkutklao Hospital, Pathumwan, TH

14:55 - 15:15 **Discussion**

15:30 - 16:45	Current standards and practice changing studies in lower gastrointestinal cancers	Channel 1
15:30 - 15:50	Practice changing studies in localized/early disease <u>T. Yoshino</u> , National Cancer Center Hospital East, Kashiwa, JP	
15:50 - 16:10	Practice changing studies in locally advanced/metastatic disease <u>A. Cervantes</u> , Hospital Clinico Universitario de Valencia, Valencia, ES	
16:10 - 16:25	An Asian patient clinical case focusing on 'Before' and 'After' the implementation of the practice-changing studies in the local/national context <u>E. Wong</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
16:25 - 16:45	Discussion	
15:30 - 16:45	Current standards and practice changing studies in genitourinary cancers	Channel 2
15:30 - 15:50	Practice changing studies in localized/early disease <u>R. Kanessvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
15:50 - 16:10	Practice changing studies in locally advanced/metastatic disease <u>T. Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB	
16:10 - 16:25	An Asian patient clinical case focusing on 'Before' and 'After' the implementation of the practice-changing studies in the local/national context <u>Y. Miura</u> , Toranomon Hospital, Minato-ku, JP	
16:25 - 16:45	Discussion	
17:00 - 18:30	Industry satellite symposium 11	Channel 1

17:00 - 18:30 Industry satellite symposium - Merck KGaA - Pfizer Oncology: Bringing Channel Patient Care to Life in Urothelial and Renal Cell Carcinomas **Channel 2**
Moderation: H. Gurney, The Crown Princess Mary Cancer Centre, Westmead, AU

17:00 - 17:05 **Welcome and Introduction**

H. Gurney, The Crown Princess Mary Cancer Centre, Westmead, AU

17:05 - 17:20 **The evolving 1L advanced bladder cancer treatment landscape in 2021**

J. Gschwend, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

17:20 - 17:35 **Integrating 1L maintenance in a patient-centered treatment approach**

S.Y. Rha, Yonsei University, Seoul, KR

17:35 - 17:55 **Metastatic RCC treatment considerations**

H. Gurney, The Crown Princess Mary Cancer Centre, Westmead, AU

17:55 - 18:30 **Sharing experiences: Treatment optimization in advanced bladder cancer and renal cell carcinoma**

H. Gurney¹, J. Gschwend², S.Y. Rha³, ¹The Crown Princess Mary Cancer Centre, Westmead, AU, ²Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, ³Yonsei University, Seoul, KR

19:00 - 20:30 Virtual Plenary **Channel 1**

19:00 - 19:10 **Presentation 1**

19:10 - 19:30 **Presentation 2**

19:30 - 19:40 **Presentation 3**

19:40 - 20:00 **Discussion**

20-11-2021

12:00 - 13:30	Industry satellite symposium 13	Channel 1
12:00 - 13:30	Industry satellite symposium - AstraZeneca	Channel 2

12:00 - 12:05 **Introduction Introduction to the faculty and overview of the meeting agenda**
Y.-L. Wu, Guangdong Province People's Hospital, Guangzhou, CN

12:05 - 12:25 **Presentation: Improving outcomes through personalised adjuvant therapy in patients with resectable EGFRm NSCLC**
M. Tsuboi, National Cancer Center Hospital East, Kashiwa, JP

12:25 - 12:45 **Live panel discussion: Optimising treatment and patient identification in resectable EGFRm NSCLC**
Y.-L. Wu¹, M.-J. Ahn², M. Tsuboi³, ¹Guangdong Province People's Hospital, Guangzhou, CN, ²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ³National Cancer Center Hospital East, Kashiwa, JP

12:45 - 13:05 **Presentation: Redefining treatment practices post-progression with first-line third-generation EGFR-TKIs in patients with metastatic EGFRm NSCLC**
M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

13:05 - 13:25 **Live panel discussion: EGFRm NSCLC in Asia: Enhancing current treatment practices in patients with metastatic disease**
Y.-L. Wu¹, M.-J. Ahn², J.C.-H. Yang³, ¹Guangdong Province People's Hospital, Guangzhou, CN, ²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ³NTUCC - National Taiwan University Cancer Center, Taipei City, TW

13:25 - 13:30 **Meeting close**
Y.-L. Wu, Guangdong Province People's Hospital, Guangzhou, CN

14:00 - 15:15 Current standards and practice changing studies in breast cancer Channel 1

- 14:00 - 14:20 **Practice changing studies in localized/early disease**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG
- 14:20 - 14:40 **Practice changing studies in locally advanced/metastatic disease**
V. Guarneri, University of Padua, Padova, IT
- 14:40 - 14:55 **An Asian patient clinical case focusing on 'Before' and 'After' the implementation of the practice-changing studies in the local/national context**
M. Sumon, Kurmitola General Hospital, Dhaka, BD
- 14:55 - 15:15 **Discussion**

14:00 - 15:15 Current standards and practice changing studies in head and neck and CNS tumours Channel 2

- 14:00 - 14:20 **Practice changing studies in CNS**
G. Minniti, University of Siena, Siena, IT
- 14:20 - 14:40 **Practice changing studies in Head Neck**
B. Keam, Seoul National University Hospital, Seoul, KR
- 14:40 - 14:55 **An Asian patient clinical case focusing on 'Before' and 'After' the implementation of the practice-changing studies in the local/national context**
W.L. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
- 14:55 - 15:15 **Discussion**

15:30 - 16:45	Current standards and practice changing studies in gynaecological cancers	Channel 1
----------------------	--	------------------

15:30 - 15:50 **Practice changing studies in cervical and endometrial Cancer**
A. Oaknin, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

15:50 - 16:10 **Practice changing studies in ovarian cancer**
S. Wilailak, Mahidol University - Faculty of Medicine, Bangkok, TH

16:10 - 16:25 **An Asian patient clinical case focusing on 'Before' and 'After' the implementation of the practice-changing studies in the local/national context**
G. El Hachem, Saint George Hospital University Medical Center, Beirut, LB

16:25 - 16:45 **Discussion**

15:30 - 16:45	Current standards and practice changing studies in sarcomas and melanomas	Channel 2
----------------------	--	------------------

15:30 - 15:50 **Practice changing studies in Sarcomas**
K. Tanaka, Oita University Faculty of Medicine, Yufu, JP

15:50 - 16:10 **Practice changing studies in Melanomas**
A. Furness, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

16:10 - 16:25 **An Asian patient clinical case focusing on 'Before' and 'After' the implementation of the practice-changing studies in the local/national context**
J. Bajpai, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN

16:25 - 16:45 **Discussion**

17:00 - 18:30 Industry satellite symposium - Amgen: Targeting KRAS in NSCLC: the path to optimising therapy **Channel 1**
Moderation: T.S.K. Mok, Clinical Oncology Department, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

17:00 - 17:05 **Welcome and introduction**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

17:05 - 17:25 **Targeting the undruggable: what we know about KRAS-mutant NSCLC**
T. Mitsudomi, Kindai University - Faculty of Medicine, Osaka, JP

17:25 - 17:45 **Optimising biomarker testing for patients with NSCLC in Asia**
T. Lim, SGH - Singapore General Hospital, Singapore, SG

17:45 - 18:05 **Expanding treatment options for patients with KRAS G12C-mutant NSCLC**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

18:05 - 18:25 **Panel discussion**

18:25 - 18:30 **Summary and close**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

17:00 - 18:30 Industry satellite symposium 16 **Channel 2**

19:00 - 20:30 Virtual Plenary **Channel 1**

19:00 - 19:10 **Presentation 1**

19:10 - 19:30 **Presentation 2**

19:30 - 19:40 **Presentation 3**

19:40 - 20:00 **Discussion**

21-11-2021

12:00 - 13:30 Industry satellite symposium - Bristol Myers Squibb: GI Cancers - I-O Regimens in the First Line and Beyond **Channel 1**

Moderation: I. Chau, Department Of Medicine, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, Surrey, GB

12:00 - 12:10 **Welcome and Introduction**

I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, Surrey, GB

12:10 - 12:30 **I-O Therapies for Gastric Cancers: Moving Toward Earlier Treatment**

T. Liu, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN

12:30 - 12:50 **The Expanding Role of I-O Therapies for Esophageal Cancer: Where Are We Today?**

H. Kawakami, Kindai University - Faculty of Medicine, Osaka, JP

12:50 - 13:05 **Practice Update - I-O Therapy in Colorectal Cancer**

I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, Surrey, GB

13:05 - 13:30 **Roundtable Discussion and Q&A: Clinical Implications of New Data**

I. Chau¹, T. Liu², H. Kawakami³, ¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, Surrey, GB, ²Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ³Kindai University - Faculty of Medicine, Osaka, JP

12:00 - 13:30	Industry satellite symposium - Ipsen: Navigating the new reality in HCC: take your seat for an open discussion	Channel 2
	Moderation: A.-L. Cheng, Department Of Oncology, NTUH - National Taiwan University Hospital, Taipei City, TW	
12:00 - 12:05	Welcome and introduction A.-L. Cheng, NTUH - National Taiwan University Hospital, Taipei City, TW	
12:05 - 12:35	Treatment sequencing: a matter of fact? A.-L. Cheng ¹ , R.K. Kelley ² , ¹ NTUH - National Taiwan University Hospital, Taipei City, TW, ² UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US	
12:35 - 13:05	Maximising efficacy and QoL: what can real-world cases teach us? L. Rimassa ¹ , L. Chan ² , ¹ Istituto Clinico Humanitas, Rozzano, IT, ² The Chinese University of Hong Kong - Sino Building, Hong Kong, CN	
13:05 - 13:10	Summary and opening for further discussion A.-L. Cheng, NTUH - National Taiwan University Hospital, Taipei City, TW	
13:10 - 13:30	Join the conversation: live discussion and Q&A	
14:00 - 15:00	Access to medicines in the Asia-Pacific region	Channel 2
14:00 - 14:15	Inequalities and disparities in access to cancer medicines in Asia R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG	
14:15 - 14:30	Are biosimilars a gamechanger? E.G.E. De Vries, UMCG - University Medical Center Groningen, Groningen, NL	
14:30 - 14:45	Case study: India's National Cancer Grid M. Sengar, Tata Memorial Hospital, Mumbai, IN	
14:45 - 15:00	Discussion and Q&A	

14:00 - 15:00 Pan-Asian adapted ESMO Clinical Practice Guidelines lecture on early colon cancer Channel 1

Moderation: A. Cervantes, Medical Oncology Department, Hospital Clinico Universitario de Valencia, Valencia, ES

14:00 - 14:20 Early colon: Presentation of the Pan-Asian adapted ESMO Clinical Practice Guideline recommendations

T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP

14:20 - 14:40 Clinical case presentation

A.M. Garcia Trinidad, DDVMH - Dagupan Doctors Villaflor Memorial Hospital, Dagupan City, PH

14:40 - 15:00 Discussion and Q&A
15:15 - 16:15 Rare cancers in Asia Channel 2
15:15 - 15:30 Rare cancers Asia: A multistakeholder partnership

P.G. Casali, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:30 - 15:45 Defining the burden of rare cancers in Asia: RARECARENET Asia

T. Matsuda, National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP

15:45 - 16:00 The growing role of patient advocacy in Asia

P. Etcheverry, Lymphoma Coalition - Head Office, Mississauga, CA

16:00 - 16:15 Discussion and Q&A

15:15 - 16:15 Pan-Asian Adapted ESMO Clinical Practice Guidelines lecture on renal cell carcinoma (RCC) Channel 1
Moderation: T. Powles, Oncology Department, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

15:15 - 15:35 **RCC: Presentation of the Pan-Asian adapted ESMO Clinical Practice Guideline recommendations**
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

15:35 - 15:55 **Clinical case presentation**
A. Tan, Waikato Hospital, Hamilton, NZ

15:55 - 16:15 **Discussion and Q&A**

16:30 - 17:30 Pan-Asian adapted ESMO Clinical Practice Guidelines lecture on head & neck cancer Channel 1
Moderation: L. Licitra, Head And Neck Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

16:30 - 16:50 **Head & neck: Presentation of the Pan-Asian adapted ESMO Clinical Practice Guideline recommendations**
B. Keam, Seoul National University Hospital, Seoul, KR

16:50 - 17:10 **Clinical case presentation**
B. Devnani, AIIMS - All India Institute of Medical Sciences, New Delhi, IN

17:10 - 17:30 **Discussion and Q&A**

22-11-2021

13:00 - 14:30 Industry satellite symposium 19 Channel 1

13:00 - 14:30 Industry satellite symposium 20 Channel 2

15:00 - 15:05 Preceptorship on Breast Cancer: Opening and welcome Channel 1

Moderation: R. Dent¹, P. Schmid², ¹Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG, ²Centre Of Experimental Cancer Medicine, Barts Cancer Institute-Queen Mary University of London, London, GB

15:00 - 15:05 **Welcome**

15:00 - 15:05 Preceptorship on Immuno-Oncology: Welcome Channel 2

Moderation: V. Atkinson, Division Of Cancer Services, Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU

15:00 - 15:05 **Welcome**

15:05 - 16:00 Preceptorship on Breast Cancer: Biology Channel 1

15:05 - 15:30 **New breast cancer classification and new technologies: What's relevant in everyday practice?**

P.H. Tan, Singapore General Hospital, Singapore, SG

15:30 - 15:50 **Prognostic and predictive markers for breast cancer management**

S. Kuemmel, Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE

15:50 - 16:00 **Discussion**

15:05 - 15:45 Preceptorship on Immuno-Oncology: Introduction Channel 2

15:05 - 15:20 **Principles of tumour immunology: Explaining cellular immunity and immune surveillance**

M. Smyth, Peter MacCallum Cancer Center, Melbourne, AU

15:20 - 15:35 **Principles of cancer immunotherapy**

I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

15:35 - 15:45 **Discussion**

15:45 - 16:55 Preceptorship on Immuno-Oncology: Clinical issues Channel 2

- 15:45 - 16:00 **Predictive biomarkers and response**
K. O'Byrne, Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU
- 16:00 - 16:15 **Clinical translation and radiological assessment of efficacy**
B.-C. Goh, National University Cancer Institute Singapore (NCIS), Singapore, SG
- 16:15 - 16:30 **Immune related toxicities and management**
I. Pires Da Silva, Melanoma Institute Australia, Wollstonecraft, AU
- 16:30 - 16:45 **Balancing costs and clinical benefit in medical oncology**
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
- 16:45 - 16:55 **Discussion**

16:10 - 17:15 Preceptorship on Breast Cancer: Local-regional treatment Channel 1

- 16:10 - 16:35 **Principles of breast surgery / oncoplastic surgery**
V. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
- 16:35 - 17:00 **Principles of breast radiation therapy**
C. Coles, University of Cambridge - Clinical Oncology - R block (R4), Cambridge, GB
- 17:00 - 17:15 **Discussion**

17:05 - 18:00 Preceptorship on Immuno-Oncology: Recent advances with ICPI: Results in approved/unapproved indication - part 1 Channel 2

- 17:05 - 17:20 **Non-Small-Cell Lung Cancer**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK
- 17:20 - 17:35 **Upper GI and colorectal**
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP
- 17:35 - 17:50 **Hepatocellular carcinoma (HCC)**
L. Chan, The Chinese University of Hong Kong - Sino Building, Hong Kong, CN
- 17:50 - 18:00 **Discussion**

17:15 - 18:20	Preceptorship on Breast Cancer: Triple Negative Breast Cancer (TNBC)	Channel 1
17:15 - 17:40	(Neo-) adjuvant systemic therapy <u>P. Schmid</u> , Barts Cancer Institute-Queen Mary University of London, London, GB	
17:40 - 18:05	Systemic therapy for metastatic TNBC <u>R. Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
18:05 - 18:20	Discussion	
18:00 - 18:40	Preceptorship on Immuno-Oncology: Audience cases	Channel 2
	Moderation: A. Furness ¹ , V. Atkinson ² , ¹ Renal And Melanoma Unit; Solid Tumour Cellular Therapy Lead, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ² Division Of Cancer Services, Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU	
18:00 - 18:40	Participants clinical case discussion	
18:20 - 18:45	Preceptorship on Breast Cancer: Clinical case discussion and Q&A	Channel 1
	Moderation: R. Dent ¹ , P. Schmid ² , ¹ Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG, ² Centre Of Experimental Cancer Medicine, Barts Cancer Institute-Queen Mary University of London, London, GB	
18:20 - 18:45	Participants clinical case discussion	
19:30 - 21:00	Industry satellite symposium 21	Channel 1

19:30 - 21:00	Industry satellite symposium - ACE Oncology: Right Patient, Right Treatment, Right Time: Expanding the Reach of Targeted Therapy in Advanced NSCLC	Channel 2
	Moderation: D.S.W. Tan, Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG	
19:30 - 19:35	Welcome and introduction <u>D.S.W. Tan</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
19:35 - 19:51	Identifying the “right patient”’: Expanding the role of NGS in detecting rare alterations in advanced NSCLC <u>K. Kerr</u> , Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB	
19:51 - 20:01	Panel discussion: Challenges in genomic profiling and interpretation of results	
20:01 - 20:01	Providing the “right treatment at the right time”	
20:01 - 20:13	Case #1 - Advanced EGFR-mutant NSCLC progressing on first-line Osimertinib <u>Y. Yu</u> , Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN	
20:13 - 20:23	Panel discussion: Identifying and tackling EGFR TKI resistance in daily practice	
20:23 - 20:35	Case #2 - Advanced NSCLC with MET ex 14 skipping mutation and PD-L1 expression <u>B.C. Cho</u> , Yonsei University, Seoul, KR	
20:35 - 20:45	Panel discussion: Treatment sequencing in patients with rare driver mutations	
20:45 - 20:57	Ask the Experts	
20:57 - 21:00	Pearls for Practice <u>D.S.W. Tan</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	

23-11-2021

13:00 - 14:30 **Industry satellite symposium - Advanced Accelerator Applications, a Novartis company: Treating What You See: Theragnostics in the Management of GEP-NETs & Prostate Cancer** **Channel 1**

13:00 - 14:30 **Lecture**

13:00 - 14:30 **Industry satellite symposium 24** **Channel 2**

15:00 - 16:35 **Preceptorship on Breast Cancer: ER+/HER2 negative breast cancer Luminal BC** **Channel 1**

15:00 - 15:25 **(Neo-) adjuvant endocrine therapy (pre and postmenopausal)**
P. Dubsky, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH

15:25 - 15:50 **How to select patients in ER+/HER2 negative BC (real practice scenario)**
J.W.-H. Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK

15:50 - 16:00 **Discussion**

16:00 - 16:25 **ET and targeted therapies for ER+/HER2 negative ABC**
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

16:25 - 16:35 **Discussion**

15:00 - 15:55 **Preceptorship on Immuno-Oncology: Recent advances with ICPI: Results in approved/unapproved indication - part 2** **Channel 2**

15:00 - 15:15 **Head and neck cancer**
W.I. Wan Zamaniah Binti, University Malaysia Specialist Centre, Kuala Lumpur, MY

15:15 - 15:30 **Gynaecological malignancies and breast cancer**
S.C. Lee, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

15:30 - 15:45 **Melanoma advanced and adjuvant**
V. Atkinson, Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU

15:45 - 15:55 **Discussion**

15:55 - 16:20	Preceptorship on Immuno-Oncology: Recent advances with ICPI: Results in approved/unapproved indication - part 3	Channel 2
15:55 - 16:10	Advanced urinary cancer (renal and bladder) <u>E. Comperat</u> , Hopital Tenon AP-HP, Paris, Cedex 20, FR	
16:10 - 16:20	Discussion	
16:30 - 17:40	Preceptorship on Immuno-Oncology: Audience cases	Channel 2
	Moderation: A. Furness ¹ , V. Atkinson ² , ¹ Renal And Melanoma Unit; Solid Tumour Cellular Therapy Lead, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ² Division Of Cancer Services, Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU	
16:30 - 17:40	Participants clinical case discussion	
16:45 - 17:25	Preceptorship on Breast Cancer: Hereditary Breast Cancer	Channel 1
16:45 - 17:15	Hereditary breast cancer <u>S. Paluch-Shimon</u> , Hadassah University Hospital - Ein Kerem, Jerusalem, IL	
17:15 - 17:25	Discussion	
17:25 - 18:30	Preceptorship on Breast Cancer: HER2+ breast cancer	Channel 1
17:25 - 17:50	(Neo-) adjuvant systemic therapy <u>S.C. Lee</u> , NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG	
17:50 - 18:15	Systemic therapy for HER2+ advanced breast cancer <u>S.-A. Im</u> , SNUH - Seoul National University Hospital, Seoul, KR	
18:15 - 18:30	Discussion	

17:40 - 18:20 Preceptorship on Immuno-Oncology: Future of immuno-oncology Channel 2
17:40 - 17:55 Cell-based therapy/Cellular therapy

A. Furness, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

17:55 - 18:10 Combination therapy: Future directions

R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

18:10 - 18:20 Discussion
18:20 - 18:25 Preceptorship on Immuno-Oncology: Closure and farewell Channel 2
18:20 - 18:25 Closure
18:30 - 18:55 Preceptorship on Breast Cancer: Clinical case discussion and Q&A Channel 1

Moderation: R. Dent¹, P. Schmid², ¹Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG, ²Centre Of Experimental Cancer Medicine, Barts Cancer Institute-Queen Mary University of London, London, GB

18:30 - 18:55 Discussion
18:55 - 19:00 Preceptorship on Breast Cancer: Closing remarks Channel 1

Moderation: R. Dent¹, P. Schmid², ¹Medical Oncology, NCCS - National Cancer Centre Singapore, Singapore, SG, ²Centre Of Experimental Cancer Medicine, Barts Cancer Institute-Queen Mary University of London, London, GB

18:55 - 19:00 Closing remarks

19:30 - 20:30	ESMO Webinar on Gastric Cancer	Channel 1
	Moderation: I. Chau, Department Of Medicine , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, Surrey, GB	
19:30 - 19:32	Introduction and welcome	
	<u>I. Chau</u> , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, Surrey, GB	
19:32 - 19:44	Incorporating checkpoint inhibitors into early line therapy and its impact on subsequent treatment in gastric/GEJ adenocarcinoma	
	<u>M. Moehler</u> , Universitätsmedizin Mainz, Mainz, DE	
19:44 - 19:56	Which, when and how to test for biomarkers in targeted therapy in gastric cancers: HER2 and beyond	
	<u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	
19:56 - 20:06	Combination strategies: Moving I-O forward in gastric cancer	
	<u>T. Nakajima</u> , St.Marianna University School of Medicine, Kawasaki, JP	
20:06 - 20:28	Clinical case based discussion: Questions and answers	
	<u>I. Chau</u> ¹ , <u>M. Moehler</u> ² , <u>H. Van Laarhoven</u> ³ , <u>T. Nakajima</u> ⁴ , ¹ The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, Surrey, GB, ² Universitätsmedizin Mainz, Mainz, DE, ³ Academic Medical Center, University of Amsterdam, Amsterdam, NL, ⁴ St.Marianna University School of Medicine, Kawasaki, JP	
20:28 - 20:30	Conclusions and perspectives	
	<u>I. Chau</u> , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, Surrey, GB	